The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 9: 1293 - 1297

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.09.019

Drugs and Clinic Practice

Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases

  • Yuxuan DING ,
  • Lining GUO ,
  • Jiayi SHEN ,
  • Lijun. WANG
Expand
  • *.Affiliated Cancer Hospital of Nanjing Medical University，Nanjing 210009，China

Received date: 2024-01-04

  Online published: 2024-05-15

Fold

Abstract

Objective To observe the efficacy and safety of radiotherapy combined with programmed death receptor?1 （PD?1） inhibitors and tyrosine kinase inhibitors （TKIs） for the treatment of microsatellite?stabilized （MSS）?type or mismatch?matched repair?normal （pMMR）?type colorectal cancer with liver metastases （CCLM）. Methods Case data of 25 patients with MSS?type CCLM admitted to Jiangsu Provincial Cancer Hospital from April 2021 to August 2023 were retrospectively analyzed. They were divided into observation group （n = 12） and control group （n = 13）. The observation group was given radiotherapy combined with PD?1 inhibitor and TKI treatment， and the control group was given TKI monotherapy. The baseline data， treatment effect， progression?free survival， and treatment?related adverse reactions of patients in the two groups were compared. Results The difference in baseline data between the two groups was not statistically significant （P > 0.05）， the disease control rate （DCR） of the observation group was higher than that of the control group （P < 0.05）， the progression?free survival （PFS） of the patients in the observation group was longer than that of the control group， but the difference was not statistically significant （P > 0.05）， and the difference in the incidence of treatment?related adverse events （TRAE） between the two groups was not statistically significant （P > 0.05）. Conclusion The treatment regimen of radiotherapy combined with PD?1 inhibitors and TKI drugs improved clinical efficacy and did not increase the incidence of adverse events when compared with TKI alone， which is a treatment regimen worthy of further validation.

Key words： colorectal cancer; radiotherapy; immune checkpoint inhibitor; tyrosine kinase inhibitors; liver metastases

Cite this article

Yuxuan DING , Lining GUO , Jiayi SHEN , Lijun. WANG . Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases[J]. The Journal of Practical Medicine, 2024 , 40(9) : 1293 -1297 . DOI: 10.3969/j.issn.1006-5725.2024.09.019

References

1 SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660
2 周雄， 胡明， 李子帅， 等. 2020年全球及中国结直肠癌流行状况分析［J］. 海军军医大学学报， 2022， 43（12）： 1356-1364.
3 MA Z H， WANG Y P， ZHENG W H， et al. Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases［J］. World J Gastrointest Oncol， 2020， 12（10）： 1177-1194. doi:10.4251/wjgo.v12.i10.1177
4 ELFRINK A K E， NIEUWENHUIZEN S， VAN DEN TOL M P， et al. Hospital variation in combined liver resection and thermal ablation for colorectal liver metastases and impact on short-term postoperative outcomes： a nationwide population-based study［J］. HPB （Oxford）， 2021， 23（6）： 827-839.
5 ZHANG Z， LIU X， CHEN D， et al. Radiotherapy combined with immunotherapy： the dawn of cancer treatment［J］. Signal Transduct Target Ther， 2022， 7（1）： 258. doi:10.1038/s41392-022-01102-y
6 LIPPERT T P， GREENBERG R A. The abscopal effect： a sense of DNA damage is in the air［J］. J Clin Invest， 2021， 131（9）： e148274. doi:10.1172/jci148274
7 YI M， JIAO D， QIN S， et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment［J］. Mol Cancer， 2019， 18（1）： 60. doi:10.1186/s12943-019-0974-6
8 EISENHAUER E A， THERASSE P， BOGAERTS J， et al. New response evaluation criteria in solid tumours： revised RECIST guideline （version 1.1）［J］. Eur J Cancer， 2009， 45（2）： 228-247. doi:10.1016/j.ejca.2008.10.026
9 CHANDRA R， KARALIS J D， LIU C， et al. The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis［J］. Cancers （Basel）， 2021， 13（24）： 6206. doi:10.3390/cancers13246206
10 STEWART C L， WARNER S， ITO K， et al. Cytoreduction for colorectal metastases： liver， lung， peritoneum， nodeslymph， bone， brain. When does it palliate， prolong survival， and potentially cure？［J/OL］. Curr Probl Surg， 2018， 55（9）： 330-379. doi:10.1067/j.cpsurg.2018.08.004
11 LI J， QIN S， XU R H， et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer： The FRESCO Randomized Clinical Trial［J］. JAMA， 2018， 319（24）： 2486-2496. doi:10.1001/jama.2018.7855
12 LI J， QIN S， XU R， et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer （CONCUR）： a randomised， double-blind， placebo-controlled， phase 3 trial［J］. Lancet Oncol， 2015， 16（6）： 619-629. doi:10.1016/s1470-2045(15)70156-7
13 DOLESCHEL D， HOFF S， KOLETNIK S， et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth［J］. J Exp Clin Cancer Res， 2021， 40（1）： 288. doi:10.1186/s13046-021-02043-0
14 SONG Y， FU Y， XIE Q， et al. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors： A Promising Strategy for Cancer Treatment［J］. Front Immunol， 2020， 11： 1956. doi:10.3389/fimmu.2020.01956
15 HUANG Y， STYLIANOPOULOS T， DUDA D G， et al. Benefits of vascular normalization are dose and time dependent--letter［J］. Cancer Res， 2013， 73（23）： 7144-7146. doi:10.1158/0008-5472.can-13-1989
16 ZHANG W， ZHANG Z， LOU S， et al. Efficacy， safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer： A retrospective study［J］. Front Oncol， 2022， 12： 929342. doi:10.3389/fonc.2022.929342
17 FUKUOKA S， HARA H， TAKAHASHI N， et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer： An Open-Label， Dose-Escalation， and Dose-Expansion Phase Ib Trial （REGONIVO， EPOC1603）［J］. J Clin Oncol， 2020， 38（18）： 2053-2061. doi:10.1200/jco.19.03296
18 MCLAUGHLIN M， PATIN E C， PEDERSEN M， et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy［J］. Nat Rev Cancer， 2020， 20（4）： 203-217. doi:10.1038/s41568-020-0246-1
19 RODRIGUEZ-RUIZ M E， RODRIGUEZ I， GARASA S， et al. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming［J］. Cancer Res， 2016， 76（20）： 5994-6005. doi:10.1158/0008-5472.can-16-0549
20 GRIMALDI A M， SIMEONE E， GIANNARELLI D， et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy［J］. Oncoimmunology， 2014， 3： e28780. doi:10.4161/onci.28780
21 CAMPHAUSEN K， MOSES M A， MéNARD C， et al. Radiation abscopal antitumor effect is mediated through p53［J］. Cancer Res， 2003， 63（8）： 1990-1993.
22 JIANG H， YU K， CUI Y， et al. Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas： Results From a Prospective Study［J］. Front Immunol， 2021， 12： 632547. doi:10.3389/fimmu.2021.632547
23 SHAVERDIAN N， LISBERG A E， BORNAZYAN K， et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer： a secondary analysis of the KEYNOTE-001 phase 1 trial［J］. Lancet Oncol， 2017， 18（7）： 895-903. doi:10.1016/s1470-2045(17)30380-7
Options
Outlines

/

〈 〉